UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): June 18, 2009

 

ImmunoGen, Inc.

(Exact name of registrant as specified in its charter)

 

 

830 Winter Street, Waltham, MA 02451

(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (781) 895-0600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

ITEM 1.01.  ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

 

On June 18, 2009, ImmunoGen, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc. as representative of the underwriters (the “Underwriters”), related to a public offering of 5,000,000 shares of the Company’s common stock, par value $.01 per share (the “Common Stock”), at a price of $7.00 per share less the underwriting commission (the “Offering”). The Offering is expected to close on June 23, 2009, subject to the satisfaction of customary closing conditions.  The net proceeds to the Company are expected to be approximately $33.0 million after deducting estimated expenses associated with the Offering. Under the terms of the Underwriting Agreement, the Company has granted the Underwriters an option, exercisable for 30 days, to purchase up to an additional 750,000 shares of Common Stock to cover over-allotments, if any, at the same price.

 

The Offering is being made pursuant to a prospectus supplement dated June 18, 2009 and an accompanying prospectus dated August 13, 2007, pursuant to the Company’s existing effective shelf registration statement on Form S-3 (File No. 333-144488), which was filed with the Securities and Exchange Commission (the “Commission”) on July 11, 2007 and declared effective by the Commission on August 13, 2007.

 

The Underwriting Agreement contains customary representations, warranties, and agreements by the Company, and customary conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties, and termination provisions.

 

A copy of the opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. relating to the legality of the issuance and sale of the shares in the Offering is attached as Exhibit 5.1 hereto.  A copy of the Underwriting Agreement is filed herewith as Exhibit 1.1 and is incorporated herein by reference.  The foregoing description of the Offering by the Company and the documentation related thereto does not purport to be complete and is qualified in its entirety by reference to such Exhibits.

 

ITEM 8.01. OTHER EVENTS

 

On June 18, 2009, the Company issued a press release announcing that it had priced the public offering described in Item 1.01 of this Current Report on Form 8-K.  The Company’s press release is filed as Exhibit 99.1 to this Report and is incorporated herein by reference.

 

ITEM 9.01.  FINANCIAL STATEMENTS AND EXHIBITS

 

(d) The following exhibits are being filed herewith:

 

Exhibit  No.		Exhibit
1.1		Underwriting Agreement dated June 18, 2009 by and among ImmunoGen,

 

2

 

		Inc. and Oppenheimer & Co. Inc. as representative of the underwriters
5.1		Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
23.1		Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in the opinion filed as Exhibit 5.1)
99.1		Press release of ImmunoGen, Inc. dated June 18, 2009

 

3

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

	ImmunoGen, Inc.
	(Registrant)
Date: June 18, 2009	/s/ Daniel M. Junius
	Daniel M. Junius
	President and Chief Executive Officer

 

4

 

EXHIBIT INDEX

 

Exhibit  No.		Exhibit
1.1		Underwriting Agreement dated June 18, 2009 by and among ImmunoGen, Inc. and Oppenheimer & Co. Inc. as representative of the underwriters
5.1		Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
23.1		Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in the opinion filed as Exhibit 5.1)
99.1		Press release of ImmunoGen, Inc. dated June 18, 2009

 

5